1. Targeting rare tumors: new focus for clinical research in China
- Author
-
Shuhang Wang, Yale Jiang, Huilei Miao, Yuan Fang, Ning Jiang, Yue Yu, Peiwen Ma, Qiyu Tang, Dandan Cui, Hong Fang, Huiyao Huang, Qi Fan, Chao Sun, Anqi Yu, Shuangman Miao, Jingting Du, Jingxiao Zhu, Yuning Wang, and Ning Li
- Subjects
Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule‐guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors.
- Published
- 2023
- Full Text
- View/download PDF